|
|
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an allosterically triggered drug-binding serpin for doxycycline== | | ==Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an allosterically triggered drug-binding serpin for doxycycline== |
| - | <StructureSection load='5om5' size='340' side='right' caption='[[5om5]], [[Resolution|resolution]] 1.59Å' scene=''> | + | <StructureSection load='5om5' size='340' side='right'caption='[[5om5]], [[Resolution|resolution]] 1.59Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[5om5]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5OM5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5OM5 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5om5]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5OM5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5OM5 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.595Å</td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">SERPINA3, AACT, GIG24, GIG25 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5om5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5om5 OCA], [http://pdbe.org/5om5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5om5 RCSB], [http://www.ebi.ac.uk/pdbsum/5om5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5om5 ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5om5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5om5 OCA], [https://pdbe.org/5om5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5om5 RCSB], [https://www.ebi.ac.uk/pdbsum/5om5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5om5 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/AACT_HUMAN AACT_HUMAN]] Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.<ref>PMID:2404007</ref> | + | [https://www.uniprot.org/uniprot/AACT_HUMAN AACT_HUMAN] Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.<ref>PMID:2404007</ref> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 19: |
Line 19: |
| | </div> | | </div> |
| | <div class="pdbe-citations 5om5" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 5om5" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Serpin 3D structures|Serpin 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Muller, Y A]] | + | [[Category: Large Structures]] |
| - | [[Category: Schmidt, K]] | + | [[Category: Muller YA]] |
| - | [[Category: Allosterically triggered drug release]] | + | [[Category: Schmidt K]] |
| - | [[Category: Alpha1-antichymotrypsin]]
| + | |
| - | [[Category: Doxycycline-binding protein]]
| + | |
| - | [[Category: Serpin]]
| + | |
| - | [[Category: Transport protein]]
| + | |
| Structural highlights
Function
AACT_HUMAN Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.[1]
Publication Abstract from PubMed
The allosteric interplay between distant functional sites present in a single protein provides for one of the most important regulatory mechanisms in biological systems. While the design of ligand-binding sites into proteins remains challenging, this holds even truer for the coupling of a newly engineered binding site to an allosteric mechanism that regulates the ligand affinity. Here it is shown how computational design algorithms enabled the introduction of doxycycline- and doxorubicin-binding sites into the serine proteinase inhibitor (serpin) family member alpha1-antichymotrypsin. Further engineering allowed exploitation of the proteinase-triggered serpin-typical S-to-R transition to modulate the ligand affinities. These design variants follow strategies observed in naturally occurring plasma globulins that allow for the targeted delivery of hormones in the blood. By analogy, we propose that the variants described in the present study could be further developed to allow for the delivery of the antibiotic doxycycline and the anticancer compound doxorubicin to tissues/locations that express specific proteinases, such as bacterial infection sites or tumor cells secreting matrix metalloproteinases.
Design of an allosterically modulated doxycycline and doxorubicin drug-binding protein.,Schmidt K, Gardill BR, Kern A, Kirchweger P, Borsch M, Muller YA Proc Natl Acad Sci U S A. 2018 May 14. pii: 1716666115. doi:, 10.1073/pnas.1716666115. PMID:29760101[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Rubin H, Wang ZM, Nickbarg EB, McLarney S, Naidoo N, Schoenberger OL, Johnson JL, Cooperman BS. Cloning, expression, purification, and biological activity of recombinant native and variant human alpha 1-antichymotrypsins. J Biol Chem. 1990 Jan 15;265(2):1199-207. PMID:2404007
- ↑ Schmidt K, Gardill BR, Kern A, Kirchweger P, Borsch M, Muller YA. Design of an allosterically modulated doxycycline and doxorubicin drug-binding protein. Proc Natl Acad Sci U S A. 2018 May 14. pii: 1716666115. doi:, 10.1073/pnas.1716666115. PMID:29760101 doi:http://dx.doi.org/10.1073/pnas.1716666115
|